Latest Healthcare News

Apiam Animal Health’s acquisition scheme by Adamantem Capital has been legally approved, leading to the suspension of its shares on the ASX. Key dates for dividend payments and scheme implementation are now set.

The Supreme Court of New South Wales has approved the scheme of arrangement for Adamantem Capital Fund II’s acquisition of Apiam Animal Health, marking a pivotal step toward the deal’s completion and the suspension of Apiam shares on the ASX.

Memphasys has raised $800,000 through a share placement to accelerate the commercial expansion of its Felix™ System, following key regulatory approvals and initial revenue milestones.

Neuren Pharmaceuticals has dosed the first patient in its groundbreaking Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome, a rare genetic disorder with no approved therapies. The trial marks a significant step forward for the PMS community and rare disease drug development.

Careteq Limited has agreed to sell its Embedded Health Solutions business for $5 million, aiming to strengthen its balance sheet and focus on expanding its home medication review platform amid ongoing tax disputes.

Imricor Medical Systems has taken a significant step toward US market entry by submitting its Advantage-MR EP Recorder/Stimulator system for FDA 510(k) clearance, aiming to enhance MRI-guided cardiac procedures.

Atomo Diagnostics has landed a significant $630,000 order to supply HIV self-tests for a federally funded Australian health initiative, reinforcing its role in expanding accessible testing.

Genetic Signatures has appointed Anne Lockwood as interim Managing Director, bringing extensive financial expertise to guide the company through a critical transition period.

Immutep Limited has reached the halfway mark in enrolling patients for its global Phase III TACTI-004 trial, testing a novel immunotherapy combo in first-line non-small cell lung cancer. The trial remains on track for key milestones this year, signaling steady progress in a critical oncology space.

Apiam Animal Health Limited has announced a special fully franked dividend of AUD 0.10 per share, with payment scheduled for mid-February 2026. Notably, the company has suspended its dividend reinvestment plan for this payout.

Apiam Animal Health has announced a fully franked special dividend of 10 cents per share, payable before the completion of its proposed acquisition by Adamantem Capital entities. The dividend is conditional on the scheme’s effectiveness and offers shareholders potential tax benefits through franking credits.

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.